Teva Pharmaceutical Industries Ltd. announced the launch of generic Epiduo1 (adapalene and benzoyl peroxide) gel, 0.1%/2.5% in the U.S.
Adapalene and benzoyl peroxide gel 0.1%/2.5% is a combination of adapalene, a retinoid, and benzoyl peroxide, and is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
“I am very pleased that Teva is introducing another first generic product, bringing value to our patients and savings to the U.S. healthcare system,” said Andy Boyer, president & CEO, Global Generic Medicines, North America.”
Teva was the first company to file a generic application for Epiduo and is expected to benefit from 180-days of generic product exclusivity. This launch marks the most recent addition to Teva’s portfolio of over 40 dermatology products.
“This is an extremely important development for Teva in our desire to make a meaningful difference to the millions of patients who suffer from acne in the U.S.,” said Hafrun Fridriksdottir, Ph.D., EVP, president of Global Generics R&D.
With close to 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.
Adapalene and benzoyl peroxide gel 0.1%/2.5% had annual sales of approximately $251 million in the U.S. according to IMS data as of March 2017.
1 Epiduo is a registered trademark of Galderma Laboratories, L.P.
(Source: Business Wire)